HC Wainwright Forecasts Agenus’ Q1 Earnings (NASDAQ:AGEN)

Agenus Inc. (NASDAQ:AGEN) – Equities research analysts at HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for Agenus in a report released on Tuesday, March 18th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will post earnings of ($1.85) per share for the quarter, up from their prior forecast of ($2.29). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share. HC Wainwright also issued estimates for Agenus’ Q2 2025 earnings at ($1.26) EPS, Q3 2025 earnings at ($0.90) EPS, Q4 2025 earnings at ($0.61) EPS, FY2025 earnings at ($4.37) EPS, FY2026 earnings at ($3.79) EPS, FY2027 earnings at ($3.25) EPS, FY2028 earnings at ($3.48) EPS and FY2029 earnings at ($2.32) EPS.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.36) by $0.32. The business had revenue of $26.84 million for the quarter, compared to analyst estimates of $30.09 million.

Separately, Robert W. Baird decreased their target price on Agenus from $6.00 to $3.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 12th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $8.75.

Agenus Price Performance

Shares of NASDAQ AGEN opened at $1.73 on Thursday. The business’s 50 day moving average price is $3.07 and its two-hundred day moving average price is $3.71. The company has a market cap of $40.58 million, a PE ratio of -0.15 and a beta of 1.23. Agenus has a twelve month low of $1.64 and a twelve month high of $19.69.

Institutional Investors Weigh In On Agenus

A number of large investors have recently added to or reduced their stakes in AGEN. B. Riley Financial Inc. acquired a new stake in Agenus during the fourth quarter worth approximately $2,074,000. Gilead Sciences Inc. acquired a new stake in Agenus during the fourth quarter worth approximately $635,000. Walleye Capital LLC acquired a new stake in Agenus during the third quarter worth approximately $1,003,000. Jane Street Group LLC grew its position in Agenus by 97.6% during the fourth quarter. Jane Street Group LLC now owns 105,705 shares of the biotechnology company’s stock worth $290,000 after buying an additional 52,215 shares in the last quarter. Finally, Deutsche Bank AG grew its position in Agenus by 538.4% during the fourth quarter. Deutsche Bank AG now owns 61,144 shares of the biotechnology company’s stock worth $168,000 after buying an additional 51,566 shares in the last quarter. Institutional investors and hedge funds own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.